Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Glaukos Corp. (GKOS)
:GKOS
GKOS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$83.90 - $163.71
Previous CloseN/A
Volume137.72K
Average Volume (3M)573.74K
Market Cap
$8.68B
Enterprise Value$7.06B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.87
Next Earnings
Apr 30, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.96
Shares Outstanding55,137,430
10 Day Avg. Volume633,288
30 Day Avg. Volume573,737
Standard Deviation0.14
R-Squared0.16
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)24.57
Price to Cash Flow (P/CF)-230.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.81
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit29.54
Enterprise Value/Ebitda-77.43
Forecast
1Y Price Target
$167.00Price Target Upside6.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
---
Bulls Say, Bears Say
Bulls Say
EarningsGlaukos Corp reported 3Q24 revenue of $96.7M, which was well ahead of analyst and consensus estimates.
Market ExpansionA broader target market for iDose addresses a wide spectrum of glaucoma severities, enhancing its adoption potential.
Product PerformanceIDose sales doubled in the third quarter to approximately $8.8M, surpassing buyside expectations.
Bears Say
Operational ChallengesManagement noted headwinds for 4Q24, including challenges in Corneal Health due to MDRP and changes in reimbursement in Surgical Glaucoma.
Revenue ForecastDespite the stronger than expected 3Q iDose showing, full-year guidance was only raised by $5mn at the midpoint versus the $4mn 3Q beat.
Valuation ConcernsThe valuation is a hurdle for many investors as shares are up significantly and sit at a high EV/sales ratio.
---
Ownership Overview
5.91% Insiders
41.96% Mutual Funds
0.19% Other Institutional Investors
26.44% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GKOS FAQ
What was Glaukos Corp.’s price range in the past 12 months?
Glaukos Corp. lowest stock price was $83.90 and its highest was $163.71 in the past 12 months.
What is Glaukos Corp.’s market cap?
Glaukos Corp.’s market cap is $8.68B.
When is Glaukos Corp.’s upcoming earnings report date?
Glaukos Corp.’s upcoming earnings report date is Apr 30, 2025 which is in 67 days.
How were Glaukos Corp.’s earnings last quarter?
Glaukos Corp. released its earnings results on Feb 20, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.383 by -$0.017.
Is Glaukos Corp. overvalued?
According to Wall Street analysts Glaukos Corp.’s price is currently Undervalued.
Does Glaukos Corp. pay dividends?
Glaukos Corp. does not currently pay dividends.
What is Glaukos Corp.’s EPS estimate?
Glaukos Corp.’s EPS estimate is -0.34.
How many shares outstanding does Glaukos Corp. have?
Glaukos Corp. has 55,137,430 shares outstanding.
What happened to Glaukos Corp.’s price movement after its last earnings report?
Glaukos Corp. reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.383. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Glaukos Corp.?
Currently, no hedge funds are holding shares in GKOS
---
Glaukos Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$167.00 (6.13% Upside)
$167.00 (6.13% Upside)
Blogger Sentiment
Bullish
GKOS Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $288.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 10.4%
Last 30 Days ▼ 10.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.80%
12-Months-Change
Fundamentals
Return on Equity
-26.10%
Trailing 12-Months
Asset Growth
-2.33%
Trailing 12-Months
Company Description
Glaukos Corp.
Glaukos Corp. is an ophthalmic medical device company, which engages in the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. Its Micro Invasive Glaucoma Surgery procedures are designed to reduce intraocular eye pressure by improving aqueous outflow through the natural physiologic pathway. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
---
GKOS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong performance with record sales growth, driven by the U.S. and international glaucoma franchises, and positive clinical developments. However, challenges such as LCD impacts, foreign exchange headwinds, and Medicaid rebate effects on corneal health were noted. The company remains optimistic about its strategic plans and financial position.Read More>---
GKOS Stock 12 Month Forecast
Average Price Target
$167.00
▲(6.13% Upside)
Technical Analysis
Align Tech
―
ICU Medical
―
Johnson & Johnson
―
Staar Surgical
―
Zimmer Biomet Holdings
―
Best Analysts Covering GKOS
1 Year
1 Year Success Rate
14/14 ratings generated profit
1 Year Average Return
+59.99%
reiterated a buy rating 4 months ago
Copying David Saxon's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +59.99% per trade.
---